Allopurinol is an oral tablet medicine for people with gout or persistently high uric acid levels. It lowers uric acid by blocking xanthine oxidase, helping prevent urate crystal buildup in joints and kidneys.
Allopurinol is a xanthine oxidase inhibitor used to lower uric acid in the body. Uric acid forms when your body breaks down purines, which come from normal cell turnover and from foods like red meat and some seafood. When uric acid stays high, it can form urate crystals that deposit in joints (gout) or the urinary tract (stones).
Each tablet contains allopurinol as the active ingredient. The usual tablet excipients may include lactose, starch, povidone, magnesium stearate, and other standard tablet-forming agents, depending on the manufacturer.
Take Allopurinol by mouth once daily, or as directed by your prescriber. It is commonly taken after food with a full glass of water to reduce stomach upset.
Hydration matters because fluid intake supports uric acid excretion through the kidneys. This does not replace the medication, but it supports the plan.
If you miss a dose, take it when you remember the same day. If it is close to the next dose, skip the missed dose and return to your normal schedule. Doubling up increases side-effect risk without improving urate control.
Allopurinol inhibits xanthine oxidase, the enzyme that helps convert purines into uric acid. By reducing uric acid production, it lowers urate levels in the blood and urine. Over time this helps prevent urate crystal deposition in joints and kidneys.
Allopurinol is converted in the body to oxypurinol, its primary active metabolite. Oxypurinol also inhibits xanthine oxidase and contributes to the medicine’s sustained urate-lowering effect.
Allopurinol is used for gout management when blood uric acid is persistently elevated or when gout attacks recur. It is also used when high uric acid increases the risk of urate kidney stones or urate deposits (tophi).
Typical reasons clinicians choose Allopurinol include:
One limitation: Allopurinol does not treat an acute gout attack by itself, and starting it during a severe flare may feel worse before it feels better.
Allopurinol is one of several ways to lower uric acid long-term. The choice depends on kidney function, prior reactions, interactions, and how far uric acid is above target.
| Option | How it lowers uric acid | When it’s often used |
|---|---|---|
| Allopurinol | Lowers production by inhibiting xanthine oxidase | First-line long-term urate lowering for many patients |
| Febuxostat | Lowers production by inhibiting xanthine oxidase | Alternative when Allopurinol is not tolerated or not suitable |
| Probenecid | Increases kidney excretion of uric acid (uricosuric) | Selected patients with under-excretion and good kidney function |
Trade-offs are real. Xanthine oxidase inhibitors reduce uric acid “at the source,” while uricosurics push more uric acid through the kidneys and can raise stone risk in susceptible patients. Many prescribers also consider cardiovascular profile and kidney disease stage when choosing between allopurinol and febuxostat, using regulator-reviewed safety information as part of that decision. [4]
Some groups need extra care with Allopurinol, mainly because drug exposure rises when clearance is reduced.
Dose and monitoring commonly change in:
This medication is NOT for you if you have had a hypersensitivity reaction to allopurinol in the past. It is also not used as a stand-alone treatment to stop an acute gout attack.
Most people tolerate Allopurinol well, yet side effects can happen. Skin reactions are the key safety topic with this medicine.
Common or reasonably expected effects in practice include:
Mild rash or itching
Nausea, diarrhoea, abdominal discomfort
Drowsiness or dizziness in some people
Temporary changes in liver enzymes on blood tests
Allopurinol Hypersensitivity Syndrome (AHS): a rare, severe reaction that can include fever, widespread rash, facial swelling, liver injury, kidney injury, and blood count abnormalities.
Severe skin reactions such as Stevens–Johnson syndrome or toxic epidermal necrolysis can start as a painful rash with blisters, mouth sores, or eye irritation.
Rare immune-related skin findings have been reported, including allopurinol-induced vascular purpura (purple spots from small-vessel inflammation).
Stop-and-get-help symptoms are straightforward: a fast-spreading rash, blistering, fever, swollen glands, shortness of breath, yellowing of the eyes, or dark urine should be treated as urgent. WHO safety communications and drug references highlight early recognition of severe cutaneous adverse reactions as a major risk-management step for allopurinol. [2]
People do not “fail” Allopurinol as much as they get tripped up by predictable patterns.
Mistakes that I see lead to poor control:
Two practical wins: keep a simple medication list in your phone, and write down the date you started Allopurinol. It helps when a clinician asks about timing in relation to side effects.
A common clinic conversation is about targets. Doctors often document a serum urate goal (frequently <6 mg/dL in guidelines) and adjust doses until that goal is met, while checking kidney function and adverse effects. NICE guidance for gout management supports a treat-to-target approach with urate-lowering therapy where appropriate. [3]
One more clinical nuance: if a patient starts Allopurinol and then stops it after a flare, they tend to repeat the same cycle of flares. Consistency beats intensity here.
Blood uric acid can begin to fall within days of starting therapy, yet the real goal is stable control over weeks to months. Gout flares may still occur early even as uric acid drops, because existing crystal deposits are being mobilised. Treatment targets and titration are typically guided by repeat blood tests and symptoms. This approach aligns with urate-lowering therapy principles described in NICE guidance (2022).
Starting during a flare is a clinical decision: some clinicians start or continue urate-lowering therapy during a flare while treating the inflammation with an anti-inflammatory plan, while others wait if the flare is severe and uncontrolled. What matters is avoiding repeated start-stop cycles that destabilise urate levels. WHO drug safety resources emphasise that management plans should include flare treatment plus long-term urate control. This is best decided with a clinician who knows your history.
Purines are broken down into uric acid during normal metabolism, and uric acid rises when production is high or kidney excretion is low. Allopurinol blocks xanthine oxidase, which sits in the pathway that converts purines into uric acid. Lower uric acid means fewer urate crystals forming in joints and kidneys over time. This mechanism is described in regulator-reviewed product information used across the EU. [5]
Azathioprine and 6-mercaptopurine must be flagged because Allopurinol can increase their toxicity sharply, and prescribers adjust doses to prevent bone marrow suppression. Warfarin also deserves attention because anticoagulation may become stronger in some patients, so INR monitoring may tighten during changes. Aspirin can influence uric acid handling, so clinicians factor it into the gout plan while keeping cardiovascular indications in mind. These interaction principles are summarised in drug interaction references used in clinical practice, including FDA labeling.
Oxypurinol is the active metabolite that provides much of the sustained urate-lowering effect after dosing. Because it is cleared mainly through the kidneys, kidney function affects how long it stays in the body. This is why dosing and monitoring are more cautious in chronic kidney disease. Pharmacology references in regulator-reviewed documents describe this metabolite contribution clearly.
Kidney impairment often requires a lower starting dose and slower titration, since both allopurinol and oxypurinol exposure can rise. Liver impairment may also need dose adjustment and periodic liver enzyme monitoring, especially if symptoms like fatigue, nausea, or dark urine appear. Drug plans often include repeat uric acid plus kidney and liver labs to balance benefit with tolerability. This risk-based approach matches urate-lowering therapy guidance used by regulators and guideline bodies.
سيتم تغليف طلبك بشكل آمن وشحنه خلال 24 ساعة. هذا هو الشكل الذي ستبدو عليه طردك بالضبط (صور لمنتج فعلي تم إرساله). له حجم ومظهر رسالة خاصة عادية (9.4×4.3×0.3 بوصة أو 24×11×0.7 سم) ولا يمكن رؤية محتوياته.
